The power of 1 in HIV therapeutics

Abstract

In this issue of Blood, Allers and colleagues describe the long-term follow-up of their previously reported HIV+ patient who was treated with allogeneic CCR5Δ32/Δ32 stem cell transplantation (SCT) for relapsed acute myeloid leukemia (AML).1,2 The patient has since remained off antiretroviral therapy (ART) and without evidence of HIV disease for 45 months after the SCT despite relapse of his AML, which necessitated a second successful transplantation.